President of the Management Board
Medical doctor, manager, innovator. He has 25 years of experience in managing pharmaceutical and biotechnological companies. A co-founder of Mabion and a long-term member of the supervisory board. A long-term president of IBSS Kraków, where he developed and implemented innovative medical solutions for the market, including original drugs. The author of eight patents, including international ones. A graduate of the Medical University of Gdańsk and MBA studies – University of Gdańsk/Copenhagen Business School/FHTW Berlin.
Member of the Board
A manager with 25 years of experience. He has been a manager at different insurance companies: Warta and Ergo Hestia. He has participated in the implementation of innovative projects and modern technologies. For nearly 10 years he has been involved in strategic consulting and creating financial policies for companies that carry out research and development activities. A graduate of Gdańsk University of Technology (Faculty of Electronics) and the University of Gdańsk (Faculty of Management).
Magdalena Wysocka graduated with a master’s degree in 2004, received a PhD in chemistry in 2008 and a post-doctoral degree in 2016. She is currently employed as a Professor at the University of Gdańsk. She is a specialist in the chemistry of peptides, peptidomimetics and proteolytic enzymes. Her scientific output includes several dozen publications from the JCR list cited over 900 times and three patents. She has managed and successfully completed four research projects.
Investment Advisor and CFA title holder. A graduate of the Warsaw School of Economics with a specialisation in finance and banking, he also studied at the Aarhus School of Business in Denmark and Universität zu Köln in Germany, and completed the CEMS MIM management programme. Scholarship holder of the Educational Enterprise Foundation. He has over 10 years of experience in asset management. He has worked for, among other organisations, the European Investment Fund in Luxembourg and Morgan Stanley in Frankfurt. In the years 2009–2020 he managed a number of different investment strategies within TFI PZU. The investment spectrum included companies from the WSE as well as those listed on EU and US exchanges. Member of the investment committee, AUM of over PLN 20 billion. Since 2014, in the position of Medical Sector Director, he has been responsible for investments in companies from the healthcare sector.
Doctor of medicine, and academic teacher at the Medical University of Warsaw. He completed a haematology specialisation course at the Department of Haematology, Transplantology and Internal Medicine at the University Clinical Centre of the Medical University of Warsaw. Founder, initiator, co-owner and president of the management board of Human Biome Institute, a modern R&D company operating in the area of biotech (human microbiota) as well as a modern laboratory and bank of human microbiota. In 2018–2021 the deputy president of the Regional Medical Chamber in Warsaw.
During his medical studies, he won numerous competitions and a scholarship of the Minister of Science and Higher Education. In 2013, he graduated from the Faculty of Medicine at Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń. He completed his doctoral course at the Medical University of Warsaw a year ahead of schedule and in 2017 defended his doctoral dissertation with distinction at the First Faculty of Medicine of Medical University of Warsaw.
Winner of the prestigious Faculty Award of Faculty V of Medical Sciences of the Polish Academy of Sciences. In 2020, he was elected “Young Ambassador of the European Society for Blood and Marrow Transplantation (EBMT)” and honoured with the “Złoty OTIS” award in the category “Scientific Début in Medicine”. His scientific interests include haematology, clinical transplantology, immunology, antibiotic resistance, metagenomics, genetics and anticancer immune response, gut microbiome and its interactions with the host.
An author of numerous full-text publications in prestigious scientific journals, post-conference abstracts and conference communications, including those presented at prestigious international congresses.
Director of research grants, co-researcher in international clinical trials, including the role of principal investigator and co-author of his own prospective clinical trial, principal investigator in an international retrospective trial within the European Society for Blood and Marrow Transplantation (EBMT) and an innovative clinical trial on the treatment of COVID19 with intestinal microbiota transplantation financed by the Medical Research Agency.
Physician, Head of the Department of Hematology, Transplantology and Internal Medicine at the University Clinical Center of Warsaw Medical University (since 2018), Chairman of the Complications Group of the European Society for Blood and Marrow Transplantation (EBMT) (since 2017). He graduated with honors from the First Faculty of Medicine of the Medical University of Warsaw (2003), obtained his PhD with distinction based on his research on experimental immunotherapy of cancer (Department of Immunology, Center of Biostructure of the Medical University of Warsaw, 2005). He completed postdoctoral fellowships at Temple University (2003, Philadelphia, USA) and University of California, San Diego (2007-2008) in experimental hematology and stem cell research.
He obtained specialization in internal medicine in 2011, in hematology (first rank) in 2014, and in clinical transplantology in 2017. Winner of, among others, START scholarship of the Foundation for Polish Science, scholarship for outstanding young scientists of the Ministry of Science and Higher Education (2012-2015). Member of the Council of Young Scientists at the Ministry of Science and Higher Education (2012-2013). Secretary of the EBMT Complications and Quality of Life Working Group (2011-2017). In 2012 he received a postdoctoral degree based on a dissertation on hematopoietic cell mobilization. Fellow of the Top500 Innovators program of the Ministry of Science and Higher Education in research management and commercialization (Cambridge and Oxford, UK, 2015).
Winner of the Pulse of Medicine “Supertalents in Medicine of the Year 2016” competition, and nominated for the Scientist of the Future 2022 award in the “Research of the Future” category (Center for Smart Growth). Since January 2019 – titular professor. Current mainstream clinical and research interests include hematopoietic cell transplantation and cancer immunotherapy, as well as the role of the gut microbiome and new technologies in hematology. Co-author of > 100 publications of international range with total IF > 740, Hirsch index 28. Co-founder of Saventic Health Sp. z o. o., a company dealing with innovative solutions in artificial intelligence in rare diseases diagnostics and Human Biome Institute.
Graduate of the Technical University of Lodz. In 1994 he obtained a securities broker license (no. 1203); issued by the Securities Commission (currently KNF). In 2002 received the Chartered Financial Analyst title (awarded by CFA Institute, Charlottesville, VA, USA). In addition, he completed a number of training courses in financial analysis, investment advisory, and asset management. He has extensive experience in supervising companies listed on the Warsaw Stock Exchange as an independent member of Supervisory Boards, including as chairman/member of Audit Committees. He served as a Supervisory Board member in such companies as: Grupa KĘTY, LPP, Drop, VRG, Libet, Interbud-Lublin.
Information on connections of Supervisory Board members with shareholders holding shares representing not less than 5% of the total number of votes at the General Meeting of the Company:
Magdalena Wysocka, being a Member of the Supervisory Board, is not connected with shareholders holding shares representing at least 5% of the total number of votes at the General Meeting of the Company.
Sławomir Kościak, Member of the Supervisory Board, is not associated with shareholders holding shares representing at least 5% of all votes at the General Meeting of the Company.
Jarosław Biliński, Member of the Supervisory Board, is not associated with shareholders holding shares representing at least 5% of all votes at the General Meeting of the Company.
Grzegorz Basak, Member of the Supervisory Board, is not associated with shareholders holding shares representing at least 5% of all votes at the General Meeting of the Company.
Maciej Matusiak, Member of the Supervisory Board, is not associated with shareholders holding shares representing at least 5% of all votes at the General Meeting of the Company.